ArticleGastroenterology report2026
Tumour Jagged1 expression as a prognostic marker of bevacizumab response and modulation of 5-fluorouracil efficacy through γ-secretase inhibition in colorectal cancer.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 5-fluorouracil (5-FU)-based chemotherapy remains the backbone of metastatic colorectal cancer (CRC) treatment, although therapeutic resistance limits long-term benefit. Combination with bevacizumab improves outcomes in some patients, but biomarkers capable of predicting benefit are lacking. Notch signalling and altered expression of its ligand Jagged1 (JAG1) have been implicated in CRC progression, yet their relevance in bevacizumab-treated patients and their regulation by 5-FU remain unclear. Methods: JAG1 protein levels were quantified in tumour samples from patients with metastatic CRC ( Results: Among patients receiving bevacizumab, those with low tumour JAG1 expression exhibited longer progression-free survival and time to progression than patients with high JAG1 expression. Conclusions: High tumour JAG1 expression identifies metastatic CRC patients with poorer outcomes when treated with a bevacizumab-containing regimen, supporting its potential as a prognostic biomarker. Mechanistically, Notch inhibition enhances the antitumour effects of 5-FU, suggesting that its combination with γ-secretase inhibitors may improve therapeutic efficacy in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.